Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2010

01.02.2010 | Original Article

Expression of hypoxia-inducible factor-1 alpha (HIF-1α) in patients with the gallbladder carcinoma

verfasst von: Erdenebulgan Batmunkh, Mitsuo Shimada, Yuji Morine, Satoru Imura, Hirofumi Kanemura, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Koji Sugimoto, Masaaki Nishi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a central role in biologic processes under hypoxic conditions, especially concerning tumor angiogenesis. Vascular endothelial growth factor (VEGF) is a potent proangiogenic agent and a multifunctional angiogenic cytokine in many malignant tumors.

Methods

This study was conducted to clarify the role of HIF-1 expression in gallbladder carcinoma. Thirty-one patients with gallbladder carcinoma underwent surgical treatment between 1994 and 2003 at the Department of Surgery, University of Tokushima, Japan. Both HIF-1α and VEGF were evaluated by immunohistochemistry, and correlations between the expression of these factors and clinicopathological features including prognosis were analyzed.

Results

Among 31 specimens from patients with gallbladder carcinoma, 22 (70%) and 9 (30%) were positive for HIF-1α and VEGF expression, respectively. Expression of HIF-1α was significantly correlated with stage, tumor curability, lymph node metastasis, venous invasion, hepatic infiltration, and lymphatic invasion (P < 0.05). The survival rate for patients with HIF-1α positive staining was significantly lower than that for patients with HIF-1α negative staining. However, VEGF overexpression did not correlate with clinical outcomes. We demonstrated that HIF-1α expression was associated with a malignant behavior risk category in gallbladder cancer.

Conclusion

Expression of HIF-1α was correlated with the poor prognostic indicators, such as lymph node metastasis and venous invasion. Therefore, HIF-1α could serve as an auxiliary parameter for predicting malignant behavior for gallbladder carcinomas.
Literatur
1.
Zurück zum Zitat Shimizu H, Kimura F, Yoshidome H et al (2007) Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. Jpn Hepatobiliary Pancreat Surg 14:358–365CrossRef Shimizu H, Kimura F, Yoshidome H et al (2007) Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. Jpn Hepatobiliary Pancreat Surg 14:358–365CrossRef
2.
Zurück zum Zitat Lee YM, Lee JY, Kim MJ et al (2006) Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 97(11):1205–1210CrossRefPubMed Lee YM, Lee JY, Kim MJ et al (2006) Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 97(11):1205–1210CrossRefPubMed
3.
Zurück zum Zitat Tanaka S, Tanaka H, Yamamoto T et al (2006) Immunohistochemical demonstration of c-Kit protooncogene product in gallbladder cancer. J Hepatobiliary Pancreat Surg 13:228–234CrossRefPubMed Tanaka S, Tanaka H, Yamamoto T et al (2006) Immunohistochemical demonstration of c-Kit protooncogene product in gallbladder cancer. J Hepatobiliary Pancreat Surg 13:228–234CrossRefPubMed
4.
Zurück zum Zitat Legan M, Luzar B, Marolt VF et al (2006) Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12(21):3425–3429PubMed Legan M, Luzar B, Marolt VF et al (2006) Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12(21):3425–3429PubMed
5.
Zurück zum Zitat Todoroki T, Kawamoto T, Takahashi H et al (1999) Treatment of gallbladder cancer by radical resection. Br J Surg 86:622–627CrossRefPubMed Todoroki T, Kawamoto T, Takahashi H et al (1999) Treatment of gallbladder cancer by radical resection. Br J Surg 86:622–627CrossRefPubMed
6.
Zurück zum Zitat Misra S, Chaturvedi A, Misra NC et al (2003) Carcinoma of the gallbladder. Oncology 4:167–176PubMed Misra S, Chaturvedi A, Misra NC et al (2003) Carcinoma of the gallbladder. Oncology 4:167–176PubMed
7.
Zurück zum Zitat Bos R, Zhong H, Hanrahan CF et al (2001) Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93(4):309–314CrossRefPubMed Bos R, Zhong H, Hanrahan CF et al (2001) Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93(4):309–314CrossRefPubMed
8.
Zurück zum Zitat Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinomas: Impact on neovascularization and survival. World J Gastroenterol 11(11):1705–1708PubMed Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinomas: Impact on neovascularization and survival. World J Gastroenterol 11(11):1705–1708PubMed
9.
Zurück zum Zitat Griffiths EA, Pritchard SA, Valentine HR et al (2006) Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96:95–103CrossRefPubMed Griffiths EA, Pritchard SA, Valentine HR et al (2006) Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96:95–103CrossRefPubMed
10.
Zurück zum Zitat Enatsu S, Iwasaki A, Shirakusa T et al (2006) Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas on the lung. Eur J Cardiothorac Surg 29:891–895CrossRefPubMed Enatsu S, Iwasaki A, Shirakusa T et al (2006) Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas on the lung. Eur J Cardiothorac Surg 29:891–895CrossRefPubMed
11.
Zurück zum Zitat Ito M, Tanaka S, Kim S et al (2003) The specific expression of hypoxia inducible factor-1α human gastric mucosa induced by non steroid and-inflammatory drugs. Aliment Pharmacol Ther 18(Suppl. 1):90–98CrossRefPubMed Ito M, Tanaka S, Kim S et al (2003) The specific expression of hypoxia inducible factor-1α human gastric mucosa induced by non steroid and-inflammatory drugs. Aliment Pharmacol Ther 18(Suppl. 1):90–98CrossRefPubMed
12.
Zurück zum Zitat Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10):2239–2245CrossRefPubMed Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10):2239–2245CrossRefPubMed
13.
Zurück zum Zitat Duncan TJ, Al-Attar A, Rolland P et al (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies. Clin Cancer Res 14(10):3030–3035CrossRefPubMed Duncan TJ, Al-Attar A, Rolland P et al (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies. Clin Cancer Res 14(10):3030–3035CrossRefPubMed
14.
Zurück zum Zitat Quan ZW, Wu K, Wang J et al (2001) Association of p53, p16, and vascular endothelial growth factor protein expression with the prognosis and metastasis of gallbladder cancer. Am Coll Surg 193(4):380–383CrossRef Quan ZW, Wu K, Wang J et al (2001) Association of p53, p16, and vascular endothelial growth factor protein expression with the prognosis and metastasis of gallbladder cancer. Am Coll Surg 193(4):380–383CrossRef
15.
Zurück zum Zitat Sumiyoshi Y, Kakeji Y, Egashira A et al (2006) Overexpression of hypoxia-inducible factor 1α and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12(17):5112–5117CrossRefPubMed Sumiyoshi Y, Kakeji Y, Egashira A et al (2006) Overexpression of hypoxia-inducible factor 1α and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12(17):5112–5117CrossRefPubMed
16.
Zurück zum Zitat Miyake K, Yoshizumi T, Imura S et al (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma correlation with poor prognosis with possible regulation. Pancreas 36:e1–e9CrossRefPubMed Miyake K, Yoshizumi T, Imura S et al (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma correlation with poor prognosis with possible regulation. Pancreas 36:e1–e9CrossRefPubMed
17.
Zurück zum Zitat Giatromanolaki A, Koukourakis MI, Simopoulos C et al (2003) Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinoma. Eur J Surg Oncol 29:879–883CrossRefPubMed Giatromanolaki A, Koukourakis MI, Simopoulos C et al (2003) Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinoma. Eur J Surg Oncol 29:879–883CrossRefPubMed
19.
Zurück zum Zitat Chen WT, Huang CJ, Wu MT et al (2005) Hypoxia-inducible factor-1α is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal. Jpn J Clin Oncol 35(4):207–213CrossRefPubMed Chen WT, Huang CJ, Wu MT et al (2005) Hypoxia-inducible factor-1α is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal. Jpn J Clin Oncol 35(4):207–213CrossRefPubMed
20.
Zurück zum Zitat Klatte T, Seligson DB, Riggs SB et al (2007) Hypoxia-inducible factor 1alpha in clear cell renal cell carcinoma. Clin Cancer Res 13(24):7388–7393CrossRefPubMed Klatte T, Seligson DB, Riggs SB et al (2007) Hypoxia-inducible factor 1alpha in clear cell renal cell carcinoma. Clin Cancer Res 13(24):7388–7393CrossRefPubMed
21.
Zurück zum Zitat Lidgren A, Hedberg Y, Grankvist K et al (2006) Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 50:1272–1277CrossRefPubMed Lidgren A, Hedberg Y, Grankvist K et al (2006) Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 50:1272–1277CrossRefPubMed
22.
Zurück zum Zitat Giatromanolki A, Sivridis E, Simopoulos S et al (2006) Hypoxia inducible factors 1α and 2α are associated With VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 94:242–247CrossRef Giatromanolki A, Sivridis E, Simopoulos S et al (2006) Hypoxia inducible factors 1α and 2α are associated With VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 94:242–247CrossRef
23.
Zurück zum Zitat Theodoropoulos VE, Lazaris AC, Sofras F et al (2004) Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200–208CrossRefPubMed Theodoropoulos VE, Lazaris AC, Sofras F et al (2004) Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200–208CrossRefPubMed
24.
Zurück zum Zitat Nadaoka J, Horikawa Y, Saito M et al (2007) Prognostic significance of HIF-1α polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 122:1297–1307CrossRef Nadaoka J, Horikawa Y, Saito M et al (2007) Prognostic significance of HIF-1α polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 122:1297–1307CrossRef
25.
Zurück zum Zitat Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas. J Surg Oncol 94:149–154CrossRefPubMed Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas. J Surg Oncol 94:149–154CrossRefPubMed
26.
Zurück zum Zitat Nikiteas NI, Tzanakis N, Theodoropoulos G et al (2007) Vascular endothelial growth factor and endolgin (CD-105) in gastric cancer. Gastric Cancer 10:12–17CrossRefPubMed Nikiteas NI, Tzanakis N, Theodoropoulos G et al (2007) Vascular endothelial growth factor and endolgin (CD-105) in gastric cancer. Gastric Cancer 10:12–17CrossRefPubMed
27.
Zurück zum Zitat Mobius C, Freire J, Becker I et al (2007) VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 10:1007 Mobius C, Freire J, Becker I et al (2007) VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 10:1007
28.
Zurück zum Zitat Bos R, Zhong H, Colleen FH et al (2001) Levels of hypoxia-inducible factor 1alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314CrossRefPubMed Bos R, Zhong H, Colleen FH et al (2001) Levels of hypoxia-inducible factor 1alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314CrossRefPubMed
29.
Zurück zum Zitat Birner P, Schindl M, Obermair A et al (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696PubMed Birner P, Schindl M, Obermair A et al (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696PubMed
30.
Zurück zum Zitat Koukourakis MI, Papazoglou D, Giatromanolaki A et al (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293–298CrossRefPubMed Koukourakis MI, Papazoglou D, Giatromanolaki A et al (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293–298CrossRefPubMed
Metadaten
Titel
Expression of hypoxia-inducible factor-1 alpha (HIF-1α) in patients with the gallbladder carcinoma
verfasst von
Erdenebulgan Batmunkh
Mitsuo Shimada
Yuji Morine
Satoru Imura
Hirofumi Kanemura
Yusuke Arakawa
Jun Hanaoka
Mami Kanamoto
Koji Sugimoto
Masaaki Nishi
Publikationsdatum
01.02.2010
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2010
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-009-0011-7

Weitere Artikel der Ausgabe 1/2010

International Journal of Clinical Oncology 1/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.